OptiNose, Inc. (OPTN)
Market Cap | 92.01M |
Revenue (ttm) | 78.23M |
Net Income (ttm) | -21.54M |
Shares Out | 10.06M |
EPS (ttm) | -2.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 93,271 |
Open | 9.15 |
Previous Close | 9.14 |
Day's Range | 9.13 - 9.17 |
52-Week Range | 4.82 - 22.35 |
Beta | -0.31 |
Analysts | Hold |
Price Target | 9.00 (-1.64%) |
Earnings Date | Mar 26, 2025 |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a l... [Read more]
Financial Performance
In 2024, OptiNose's revenue was $78.23 million, an increase of 10.20% compared to the previous year's $70.99 million. Losses were -$21.54 million, -39.29% less than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OPTN stock is "Hold." The 12-month stock price forecast is $9.0, which is a decrease of -1.64% from the latest price.
News

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiN...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea...

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 ‑ million ‑ patient market Acquisition advances Paratek's ...

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% Preliminary XHANCE prescription growth rate from third quarter to fourth quarter...

Optinose Announces 1-for-15 Reverse Stock Split
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announc...

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jonathan Neely - Vice President of Investor Relations and Business Development Ramy Mah...

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q3 2024 XHANCE net revenue of $20.4 million , an increase of 3% compared to Q3 2023

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...

Optinose Appoints Terry Kohler as Chief Financial Officer
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief C...

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time

Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Partic...

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expe...

Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time

Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Conference Call March 7, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Ramy Mahmoud - CEO Conference Call Participa...